Clinical Trial Update: Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of Rufinamide in children aged 1 to <4 years with Lennox-Gastaut Syndrome; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lennox-gastaut Syndrome

Drugs mentioned

• Rufinamide (Rufinamide)

Snippet

Sponsor: Eisai Inc. | Conditions: Lennox-Gastaut Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2019-08-06